Assessing the Ompact of Neutral Pelvic Positioning on Bone Repositioning Quality in Pelvic Radiotherapy Patients
- Conditions
- Registration Number
- NCT06687200
- Lead Sponsor
- Centre Leon Berard
- Brief Summary
This study explores whether achieving a neutral pelvic position improves bone repositioning quality for patients undergoing pelvic radiotherapy. While Intensity-Modulated Radiotherapy (IMRT) and Image-Guided Radiotherapy (IGRT) have enhanced target volume precision and reduced side effects, effective patient positioning remains crucial. However, rotational a...
- Detailed Description
Radiotherapy (RT) is an integral part of curative treatment for pelvic cancers. Intensity-Modulated Radiotherapy (IMRT) has demonstrated benefits in target volume (TV) coverage and sparing healthy tissues. IMRT achieves a highly conformal dose distribution, with steep dose gradients between the TVs and Organs at Risk (OARs). However, its effectiveness depend...
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Female
- Target Recruitment
- 200
I1. Female, aged ≥ 18 years; I2. Patient scheduled for intensity-modulated radiotherapy for pelvic cancer, with an irradiation field extending at least up to L5-S1 on an accelerator equipped with a 3D imaging system (CBCT or MVCT) with automatic registration; I3. Patient affiliated with a social security scheme or equivalent; I4. Dated and signed informed consent.
E1. Patient unable or unwilling to lift the pelvis; E2. Patient with anal or vulvar carcinoma; E3. Patient with unstable spondylolisthesis; E4. Patient with an unhealed lumbar or pelvic fracture; E5. Patient with a recent muscle injury in the relevant muscle groups; E6. Patient with an ECOG performance status ≥ 2; E7. Pregnant or breastfeeding patient.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The rate of images with RX > 3° will be calculated for each patient as the number of sessions with a repositioning image where RX is > 3°, relative to the total number of sessions performed. At to 3 months
- Secondary Outcome Measures
Name Time Method The median, mean, and standard deviation of rotations (RX, RY, and RZ) obtained from the positioning imaging; At to 3 months The median, mean, and standard deviation of translations (TX, TY, and TZ) obtained from the positioning imaging At to 3 months The calculation of the dose delivered to nodal CTVs and organs at risk, recalculated by simulating the actual rotations observed during treatment At to 24 months Gastrointestinal, urinary, and hematological toxicities graded according to NCI-CTCAE v5 Up to 24 months Systematic error estimation calculated using the Van Herk et al. formula At to 24 months Random error estimation calculated using the Van Herk et al. formula At to 24 months Estimation of nodal CTV-PTV margins calculated using the Van Herk et al. formula At to 24 months Evaluation of repositioning error in relation to L4, without applying rotations, will be obtained using the mean and standard deviation of measurements between the anterosuperior part of the L4 vertebral body on the reference image and on the daily image At to 3 months For irradiations including lombo-aortic nodal areas only
Evaluation of the RX rotation discrepancy observed after registering the daily image to the reference image, comparing two regions of interest: one defined by L1-L5 and the other defined from the iliac crests to the ischial tuberosities At to 24 months For irradiations including lombo-aortic nodal areas only
Trial Locations
- Locations (4)
Centre Leon Berard
🇫🇷Lyon, France
Institut de Cancérologie de Lorraine
🇫🇷Nancy, France
Centre Eugène Marquis
🇫🇷Rennes, France
Institut de Cancérologie de l'Ouest - Saint-Herblain
🇫🇷Saint-Herblain, France